Zinc Acetate Anhydrous
drugOn this page
Also known as Acetic acid, zinc(ii) saltAnhydrous zinc acetateE650NSC-75801Zincum aceticumZinc acetateSID144212333
Summary
Zinc Acetate Anhydrous (CHEMBL1200928) is an approved small-molecule astringent; indicated across 5 conditions including pneumonia and wilson disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 5 conditions
- Clinical trials: 12
- Chemistry: 183.5 Da · C4H6O4Zn
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200928 |
| Name | Zinc Acetate Anhydrous |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 11192 |
| ChEBI | CHEBI:62984 |
| Molecular formula | C4H6O4Zn |
| Molecular weight | 183.5 |
| InChIKey | DJWUNCQRNNEAKC-UHFFFAOYSA-L |
SMILES: CC(=O)[O-].CC(=O)[O-].[Zn+2]
IUPAC name: zinc diacetate
ChEBI definition: An acetate salt in which the cationic component is zinc(2+).
Pharmacological roles (ChEBI): astringent.
Also known as: Acetic acid, zinc(ii) salt, Anhydrous zinc acetate, E650, NSC-75801, Zinc acetate anhydrous, Zincum aceticum, Zinc acetate, SID144212333, ZINC ACETATE ANHYDROUS
Parent form; salt/anhydrous children: CHEMBL3184986
Patent coverage: 44,972 distinct patent families (101,441 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 100,605 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| pneumonia | 3 | MONDO:0005249 | EFO:0003106 |
| Wilson disease | 3 | MONDO:0010200 | MONDO:0010200 |
| stomatitis | 2 | MONDO:0004842 | EFO:1001904 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00004338 | PHASE4 | COMPLETED | Study of Zinc for Wilson Disease |
| NCT05778383 | PHASE4 | COMPLETED | Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes |
| NCT00212368 | PHASE3 | COMPLETED | Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. |
| NCT00373100 | PHASE3 | COMPLETED | The Efficacy of Zinc as Adjunct Therapy in the Treatment of Severe Pneumonia in Children |
| NCT02868151 | PHASE2/PHASE3 | COMPLETED | Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers |
| NCT04621149 | PHASE2 | TERMINATED | An Outpatient Study Investigating Non-prescription Treatments for COVID-19 |
| NCT00696410 | PHASE1 | COMPLETED | The Impact of Zinc Supplementation on Left Ventricular Function in Nonischemic Cardiomyopathy |
| NCT06612554 | Not specified | RECRUITING | Zn Supplementation in HIV Immunological Non Responders |
| NCT00981448 | Not specified | COMPLETED | Nutrigenomics of Zinc Supplementation in Insulin Secretion and Diabetes |
| NCT03532555 | Not specified | TERMINATED | Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia |
| NCT04828538 | Not specified | WITHDRAWN | Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19 |
| NCT05095493 | Not specified | COMPLETED | Oral Zinc Supplementation to Enhance Botulinum Neurotoxin Response |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: pneumonia, Wilson disease